Results 221 to 230 of about 31,567 (277)

JAK inhibition in PD-1 immunotherapy and tumor microenvironment. [PDF]

Front Immunol
Liu Z, Liu J, Chu H, Lu Z, Xu S, Qin Y, Zhao L, Zhang C.   +7 more
europepmc   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

Journal of the European Academy of Dermatology and Venereology, EarlyView.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta, Julia Steriopoulos, Vasiliki Economopoulos, Paradi Mirmirani, Vincent Piguet   +4 more
wiley   +1 more source

Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling. [PDF]

Int J Mol Sci
Wang PC, Yu S.
europepmc   +1 more source

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This international, multicentre real‐world study of 148 patients’ documents treatment‐associated, bidirectional phenotype switching between psoriasis and atopic dermatitis. Psoriasis‐to‐eczematous switches occurred predominantly with IL‐17 and IL‐23 inhibitors, whereas AD‐to‐psoriasiform switches occurred exclusively during treatment with biologic ...
Tiago Torres, Mario Valenti, Anna Balato, Matteo Megna, Paolo Gisondi, Vimal Prajapati, Stefano Piaserico, Julia‐Tatjana Maul, Lara Valeska Maul, Jose Manuel Carrascosa, Francisco José Navarro‐Triviño, Elizabeth Lazaridou, César Ferreira, Jacopo Tartaglia, Christian Ciolfi, Athina‐Ioanna Daponte, Eugenia Veronica Di Brizzi, Maddalena Napolitano, Barbara Leal Guerra, Monica Munera‐Campos, Siddhartha Sood, Silvia Ferruci, Francesca Prignano, Esteban Dauden, Mar Llamas‐Velasco, Ron Vender, Jensen Yeung, Angelo Marzano, Luis Puig   +28 more
wiley   +1 more source

Engineered Fenretinide- and Tocilizumab-Releasing Janus Nanoparticles for Site-Directed Immunochemoprevention of Squamous Cell Carcinoma of the Lung. [PDF]

Pharmaceutics
Wang D, Chang A, Shea F, He Y, Spinney R, Whitsett JD, Lahann J, Mallery SR.   +7 more
europepmc   +1 more source

Large‐scale meta‐analysis of infection risk with JAK–STAT inhibitors in 29,000 patients

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this large meta‐analysis of 74 randomized controlled trials involving more than 29,000 patients, JAK–STAT inhibitors were associated with an increased risk of influenza, bronchitis and herpes infections, particularly herpes zoster, while an increased risk of serious opportunistic or fungal infections was not observed.
Máté Krebs, Lili Gulyás, Karen Krisztina Fazekas, Benedek Nagy, Mária Veronika Kolonics, Fanni Adél Meznerics, Norbert Kiss, András Bánvölgyi, Péter Hegyi, Péter Holló, Lajos Vince Kemény   +10 more
wiley   +1 more source

Diversifying the triquinazine scaffold of a Janus kinase inhibitor. [PDF]

RSC Med Chem
Mulliri K, Meier K, Feuchter JD, Javor S, Meirelles MA, Reymond JL.   +5 more
europepmc   +1 more source

Molecular basis and cellular effects of Janus-class-driven cytoplasmic PYK2 coacervates. [PDF]

Commun Biol
Colombo G, Salem I, Szczepski K, Yu P, Alfaiyz S, Guzmán-Vega FJ, Abogosh A, Kulmanov M, Al-Harthi S, Kadaré G, Hoehndorf R, Girault JA, Jaremko Ł, Momin AA, Arold ST.   +14 more
europepmc   +1 more source

Signaling pathways in systemic lupus erythematosus and therapeutic implications. [PDF]

Front Immunol
Balogh L, Kovács VG, Nagy G, Németh T.
europepmc   +1 more source